

**CAR T-cell Therapy Market Size, Share & Trends by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target Antigen (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), End User & Region - Global Forecast to 2029**

Market Report | 2024-07-22 | 266 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The global CAR T-cell therapy market is estimated to reach USD 29.0 Billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 39.6% during the forecast period of 2024 to 2029. Market growth is driven by the rise in the global cancer prevalence. Technological advancements in CAR T-cell therapies and rising therapy development investment and funding is likely to propel the market growth. However, adverse effects associated with CAR T-cell therapy and high treatment costs are some of the major factors expected to restrain the market growth during the forecast period.

"Yescarta segment accounted for the highest share of 2023."

Based on product, the CAR T-cell therapy market is broadly segmented into Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Kymriah (tisagenlecleucel) and other products. The Yescarta segment held the largest market share in 2023. Market growth is attributed to high response rates and durable remissions of Yescarta in treating relapsed/refractory cancers leading to an increase in therapy adoption.

"The Hospitals End User segment held the dominant share in the CAR T-cell therapy market."

Based on end users, the global CAR T-cell therapy market is segmented into hospitals, long term care facilities and specialty centers. In 2023, the hospitals segment emerged as the primary growth driver in the global CAR T-cell therapy market, with the highest CAGR during the forecast period. Hospitals are incorporating CAR T-cell therapies into their standard oncology treatment

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

protocols. This trend is boosting demand for CAR T-cell treatments as more hospitals embrace these therapies. Furthermore, hospitals play a key role in facilitating clinical trials for CAR T-cell therapies. By actively participating in research initiatives and collaborations with pharmaceutical companies, hospitals contribute to expanding the evidence base and accelerating regulatory approvals, which in turn stimulates market growth.

"Asia Pacific region estimated to show fastest growth rate."

The CAR T-cell therapy market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. During the forecast period, Asia Pacific region is estimated to grow at the highest CAGR. The supportive regulatory frameworks, rich CAR T-cell therapy product pipeline and expedited approval processes facilitate quicker market entry for innovative therapies, driving growth in the Asia Pacific market. In addition, increasing collaborations between hospitals, universities, and industries in China are expected to provide lucrative market growth. The rapid increase in clinical trials evaluating the safety and effectiveness of CAR T-cell therapy across diverse cancer types in China also signals significant advancements. These studies have demonstrated encouraging results in treating leukemia, lymphoma, and solid tumors, with specific patient cohorts showing substantial rates of complete remission and sustained responses. This trend highlights Asia Pacific's progress in developing and validating CAR T-cell treatments, positioning the region as a key player in advancing therapeutic outcomes in oncology in CAR T-cell therapy.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 70%, and Demand Side - 30%
- By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, MEA- 5%

List of Companies Profiled in the Report:

- Bristol-Myers Squibb Company (US)
- Gilead Sciences Inc. (US)
- Novartis AG (Switzerland)
- Johnson & Johnson (US)
- CARsgen Therapeutics Holdings Limited (China)
- IASO Biotherapeutics (China)
- W (Cayman) Therapeutics Co. Ltd (China)
- ImmunoAct (India)
- CRISPR Therapeutics (Switzerland)
- Autolus Therapeutics (UK)
- Allogene Therapeutics (US)
- Cartesian Therapeutics Inc. (US)
- Guangzhou Bio-gene Technology Co. Ltd (China)
- Wugen (US).

Research Coverage:

This report provides a detailed picture of the CAR T-cell therapy market. It aims to estimate the size and future growth potential of the market across different segments, such as product, target, demographic, indications, end-users and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall CAR T-cell therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (technological advancements in CAR T-cell therapies, growing cancer prevalence, and rising investment and funding for therapy development), restraints (high therapy costs and adverse effects), opportunities (expansion into solid tumors and collaborations and partnerships) and challenges (patient recruitment for trials and reimbursement issues) are influencing the growth of CAR T-cell therapy market.
- Product Development/Innovation: Detailed insights on newly launched products of the CAR T-cell therapy market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the CAR T-cell therapy market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CAR T-cell therapy market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Bristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Johnson & Johnson (US), JW (Cayman) Therapeutics Co. Ltd (China), ImmunoAct (India), among others in the CAR T-cell therapy market.

## **Table of Contents:**

1□INTRODUCTION□	25
1.1□STUDY OBJECTIVES□	25
1.2□MARKET DEFINITION□	25
1.2.1□INCLUSIONS & EXCLUSIONS□	26
1.3□MARKET SCOPE□	26
1.3.1□MARKETS COVERED□	26
1.3.2□REGIONS COVERED□	27
1.3.3□YEARS CONSIDERED□	27
1.3.4□CURRENCY CONSIDERED□	28
1.4□STAKEHOLDERS□	28
1.5□RECESSION IMPACT□	28
2□RESEARCH METHODOLOGY□	29
2.1□RESEARCH DATA□	29
2.1.1□SECONDARY DATA□	30
2.1.2□PRIMARY DATA□	31
2.1.3□BREAKDOWN OF PRIMARIES□	31
2.2□MARKET SIZE ESTIMATION□	32
2.2.1□INSIGHTS FROM PRIMARY EXPERTS□	35
2.2.2□SEGMENTAL MARKET SIZE ESTIMATION□	36
2.3□GROWTH RATE ASSUMPTIONS□	37
2.3.1□CAGR PROJECTIONS□	37
2.3.2□IMPACT OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS□	38
2.4□VOLUME ESTIMATION□	38
2.5□MARKET BREAKDOWN AND DATA TRIANGULATION□	39
2.6□RESEARCH LIMITATIONS□	40
2.7□STUDY ASSUMPTIONS□	40
2.8□RISK ANALYSIS□	41
2.9□RECESSION IMPACT ANALYSIS□	41
3□EXECUTIVE SUMMARY□	42
4□PREMIUM INSIGHTS□	46

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

4.1	CAR T-CELL THERAPY MARKET OVERVIEW	46
4.2	NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT AND COUNTRY (2023)	47
4.3	CAR T-CELL THERAPY MARKET SHARE, BY PRODUCT	48
4.4	CAR T-CELL THERAPY MARKET, BY END USER	48
	?	
5	MARKET OVERVIEW	49
5.1	INTRODUCTION	49
5.2	MARKET DYNAMICS	49
5.2.1	DRIVERS	50
5.2.1.1	Growing cancer prevalence	50
5.2.1.2	Technological advancements in CAR T-cell therapies	50
5.2.1.3	Rising investment and funding for therapy development	51
5.2.2	RESTRAINTS	52
5.2.2.1	High therapy costs	52
5.2.2.2	Adverse effects	53
5.2.3	OPPORTUNITIES	54
5.2.3.1	Expansion into solid tumors	54
5.2.3.2	Collaborations and partnerships	55
5.2.4	CHALLENGES	57
5.2.4.1	Patient recruitment for trials	57
5.2.4.2	Reimbursement issues	57
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	59
5.4	VALUE CHAIN ANALYSIS	60
5.5	ECOSYSTEM ANALYSIS	62
5.5.1	PRODUCTS	62
5.5.2	END USERS	63
5.5.3	REGULATORY BODIES	64
5.6	TECHNOLOGY ANALYSIS	65
5.6.1	KEY TECHNOLOGIES	65
5.6.1.1	CAR DESIGN AND OPTIMIZATION	65
5.6.1.2	VIRAL VECTOR TECHNOLOGY	65
5.6.1.3	CELL CULTURE AND EXPANSION TECHNIQUES	65
5.6.2	COMPLIMENTARY TECHNOLOGIES	66
5.6.2.1	GENE EDITING TECHNOLOGY (CRISPR-CAS9-BASED GENOME EDITING)	66
5.6.3	ADJACENT TECHNOLOGIES	67
5.6.3.1	MONITORING AND IMAGING TECHNOLOGIES	67
5.7	PATENT ANALYSIS	67
5.7.1	METHODOLOGY	68
5.7.2	NUMBER OF PATENTS FILED	68
5.7.3	INNOVATION AND PATENT APPLICATIONS	68
5.7.4	TOP APPLICANTS	69
5.8	PRICING ANALYSIS	71
5.8.1	AVERAGE SELLING PRICE, BY TYPE	72
5.8.2	AVERAGE SELLING PRICE, BY REGION	73
5.8.3	AVERAGE SELLING PRICE TREND, BY PRODUCT	74
	?	
5.9	KEY CONFERENCES & EVENTS, 2024-2025	75

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

5.10	REGULATORY LANDSCAPE	76
5.10.1	REGULATORY SCENARIO	76
5.10.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	77
5.11	INVESTMENT & FUNDING SCENARIO	80
5.12	PORTER'S FIVE FORCES ANALYSIS	81
5.12.1	INTENSITY OF COMPETITIVE RIVALRY	82
5.12.2	BARGAINING POWER OF SUPPLIERS	82
5.12.3	BARGAINING POWER OF BUYERS	82
5.12.4	THREAT OF SUBSTITUTES	82
5.12.5	THREAT OF NEW ENTRANTS	82
5.13	KEY STAKEHOLDERS & BUYING CRITERIA	83
5.13.1	KEY BUYING CRITERIA	84
6	CAR T-CELL THERAPY MARKET, BY PRODUCT	86
6.1	INTRODUCTION	87
6.2	YESCARTA	88
6.2.1	INCREASING REACH TO DRIVE MARKET	88
6.3	KYMRIAH	90
6.3.1	APPROVAL FOR PEDIATRIC USE TO SUPPORT MARKET GROWTH	90
6.4	CARVYKTI	92
6.4.1	WIDESPREAD REACH TO ENSURE MARKET GROWTH	92
6.5	ABECMA	95
6.5.1	RIISING RESEARCH FOR ALTERNATIVE INDICATIONS TO DRIVE MARKET	95
6.6	TECARTUS	97
6.6.1	GROWING FOCUS ON PATIENT-CENTRIC REIMBURSEMENT TO PROPEL MARKET	97
6.7	BREYANZI	99
6.7.1	MULTIPLE INDICATIONS TO PROPEL MARKET GROWTH	99
6.8	OTHER PRODUCTS	102
7	CAR T-CELL THERAPY MARKET, BY TARGET	106
7.1	INTRODUCTION	107
7.2	CD19	107
7.2.1	RIISING INDICATIONS IN PIPELINE TO DRIVE MARKET	107
7.3	BCMA	110
7.3.1	TECHNOLOGICAL ADVANCEMENTS IN CAR T-CELL THERAPY TO PROPEL MARKET GROWTH	110
7.4	OTHER TARGETS	113
?		
8	CAR T-CELL THERAPY MARKET, BY INDICATION	117
8.1	INTRODUCTION	118
8.2	MULTIPLE MYELOMA	118
8.2.1	RIISING INCIDENCE OF MULTIPLE MYELOMA TO DRIVE MARKET	118
8.3	B-CELL LYMPHOMA	121
8.3.1	RIISING PREVALENCE TO PROPEL MARKET GROWTH	121
8.4	ACUTE LYMPHOBLASTIC LEUKEMIA	123
8.4.1	FOCUS ON AFFORDABLE CAR T-CELL THERAPIES TO DRIVE MARKET	123
8.5	OTHER INDICATIONS	126
9	CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC	130
9.1	INTRODUCTION	131

9.2	ADULTS	131
9.2.1	INCREASING NUMBER OF LYMPHOMAS TO DRIVE MARKET	131
9.3	PEDIATRICS	133
9.3.1	RIISING PREVALENCE OF TARGET DISEASES TO PROPEL MARKET GROWTH	133
10	CAR T-CELL THERAPY MARKET, BY END USER	137
10.1	INTRODUCTION	138
10.2	HOSPITALS	138
10.2.1	GROWING PREVALENCE OF CANCER TO DRIVE MARKET	138
10.3	SPECIALTY CENTERS	140
10.3.1	GROWING RESEARCH COLLABORATIONS TO PROPEL MARKET	140
10.4	LONG-TERM CARE FACILITIES	143
10.4.1	GROWING CASES OF CHRONIC DISORDERS TO DRIVE MARKET	143
11	CAR T-CELL THERAPY MARKET, BY REGION	146
11.1	INTRODUCTION	147
11.2	NORTH AMERICA	147
11.2.1	NORTH AMERICA: RECESSION IMPACT	147
11.2.2	US	151
11.2.2.1	Rising R&D activities for CAR T-cell therapies to drive market	151
11.2.3	CANADA	154
11.2.3.1	Government initiatives for regenerative medicine research to drive market	154
11.3	EUROPE	156
11.3.1	EUROPE: RECESSION IMPACT	156
11.3.2	GERMANY	159
11.3.2.1	Rising focus on clinical research to drive market	159
11.3.3	UK	162
11.3.3.1	Rising technological advancements in automation to drive market	162
11.3.4	FRANCE	164
11.3.4.1	Growing focus on cell & gene therapy initiatives to boost demand	164
11.3.5	ITALY	167
11.3.5.1	Growth in biotech sector to drive market	167
11.3.6	SPAIN	169
11.3.6.1	Rising focus on cell therapies to support market growth	169
11.3.7	REST OF EUROPE	171
11.4	ASIA PACIFIC	174
11.4.1	ASIA PACIFIC: RECESSION IMPACT	174
11.4.2	CHINA	178
11.4.2.1	Rising number of CAR T-cell clinical trials to support market growth	178
11.4.3	JAPAN	181
11.4.3.1	Increasing product approvals to drive market	181
11.4.4	INDIA	183
11.4.4.1	Rising incidence of cancer and growing focus on product commercialization to boost demand	183
11.4.5	AUSTRALIA	185
11.4.5.1	Robust infrastructure for clinical trials and well-developed healthcare sector to drive market	185
11.4.6	SOUTH KOREA	188
11.4.6.1	Rising growth in biopharmaceutical industry to drive market	188
11.4.7	REST OF ASIA PACIFIC	190
11.5	LATIN AMERICA	192

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.5.1	LATIN AMERICA: RECESSION IMPACT	192
11.5.2	BRAZIL	195
11.5.2.1	High expenditure on healthcare to support market growth	195
11.5.3	REST OF LATIN AMERICA	198
11.6	MIDDLE EAST & AFRICA	200
11.6.1	MEA TO GROW AT SLOWER PACE DURING FORECAST PERIOD	200
11.6.2	MIDDLE EAST & AFRICA: RECESSION IMPACT	201
12	COMPETITIVE LANDSCAPE	204
12.1	OVERVIEW	204
12.2	KEY PLAYER STRATEGY/RIGHT TO WIN	204
12.2.1	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CAR T-CELL THERAPY MARKET	205
12.3	REVENUE ANALYSIS	206
12.4	MARKET SHARE ANALYSIS	207
12.4.1	RANKING OF KEY MARKET PLAYERS	209
12.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	209
12.5.1	STARS	209
12.5.2	EMERGING LEADERS	210
12.5.3	PERVASIVE PLAYERS	210
12.5.4	PARTICIPANTS	210
12.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	211
12.5.5.1	Company footprint	211
12.5.5.2	Product footprint	211
12.5.5.3	Target footprint	212
12.5.5.4	Indication footprint	212
12.5.5.5	Region footprint	213
12.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	213
12.6.1	PROGRESSIVE COMPANIES	213
12.6.2	RESPONSIVE COMPANIES	213
12.6.3	DYNAMIC COMPANIES	214
12.6.4	STARTING BLOCKS	214
12.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	215
12.7	VALUATION & FINANCIAL METRICS	216
12.7.1	FINANCIAL METRICS	216
12.7.2	COMPANY VALUATION	216
12.8	BRAND/PRODUCT COMPARISON	217
12.9	COMPETITIVE SCENARIO	218
12.9.1	PRODUCT LAUNCHES & APPROVALS	218
12.9.2	DEALS	219
12.9.3	EXPANSIONS	220
12.9.4	OTHER DEVELOPMENTS	220
13	COMPANY PROFILES	221
13.1	KEY PLAYERS	221
13.1.1	BRISTOL-MYERS SQUIBB COMPANY	221
13.1.1.1	Business overview	221
13.1.1.2	Products offered	223
13.1.1.3	Recent developments	223

- 13.1.1.3.1□Product approvals□223
- 13.1.1.3.2□Deals□225
- 13.1.1.4□MnM view□225
- 13.1.1.4.1□Key strengths□225
- 13.1.1.4.2□Strategic choices□225
- 13.1.1.4.3□Weaknesses & competitive threats□225
- 13.1.2□GILEAD SCIENCES, INC.□226
- 13.1.2.1□Business overview□226
- 13.1.2.2□Products offered□228
- 13.1.2.3□Recent developments□229
- 13.1.2.3.1□Product approvals□229
- 13.1.2.3.2□Deals□229
- 13.1.2.3.3□Other developments□230
- ?
- 13.1.2.4□MnM view□230
- 13.1.2.4.1□Key strengths□230
- 13.1.2.4.2□Strategic choices□231
- 13.1.2.4.3□Weaknesses & competitive threats□231
- 13.1.3□NOVARTIS AG□232
- 13.1.3.1□Business overview□232
- 13.1.3.2□Products offered□234
- 13.1.3.3□Recent developments□235
- 13.1.3.3.1□Product launches & approvals□235
- 13.1.3.3.2□Expansions□235
- 13.1.3.3.3□Other developments□236
- 13.1.3.4□MnM view□236
- 13.1.3.4.1□Key strengths□236
- 13.1.3.4.2□Strategic choices□236
- 13.1.3.4.3□Weaknesses and competitive threats□236
- 13.1.4□JOHNSON & JOHNSON□237
- 13.1.4.1□Business overview□237
- 13.1.4.2□Products offered□238
- 13.1.4.3□Recent developments□239
- 13.1.4.3.1□Product approvals□239
- 13.1.4.3.2□Deals□239
- 13.1.5□JW (CAYMAN) THERAPEUTICS CO. LTD.□240
- 13.1.5.1□Business overview□240
- 13.1.5.2□Products offered□241
- 13.1.5.3□Recent developments□241
- 13.1.5.3.1□Product approvals□241
- 13.1.5.3.2□Deals□242
- 13.1.6□IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT)□243
- 13.1.6.1□Business overview□243
- 13.1.6.2□Products offered□243
- 13.1.6.3□Recent developments□244
- 13.1.6.3.1□Deals□244
- 13.1.6.3.2□Other developments□245

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



13.1.7	CARSGEN THERAPEUTICS HOLDINGS LIMITED	246
13.1.7.1	Business overview	246
13.1.7.2	Products offered	247
13.1.7.3	Recent developments	247
13.1.7.3.1	Product approvals	247
13.1.7.3.2	Deals	248
13.1.7.3.3	Expansions	249
?		
13.1.8	IASO BIOTHERAPEUTICS	250
13.1.8.1	Business overview	250
13.1.8.2	Products offered	250
13.1.8.3	Recent developments	251
13.1.8.3.1	Product approvals	251
13.1.8.3.2	Deals	251
13.2	OTHER PLAYERS	252
13.2.1	GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD (HEDY GROUP CO., LTD.)	252
13.2.2	CARTESIAN THERAPEUTICS, INC.	253
13.2.3	AUTOLUS THERAPEUTICS	254
13.2.4	ALLOGENE THERAPEUTICS	255
13.2.5	CRISPR THERAPEUTICS	256
13.2.6	WUGEN	257
14	APPENDIX	258
14.1	DISCUSSION GUIDE	258
14.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	262
14.3	CUSTOMIZATION OPTIONS	264
14.4	RELATED REPORTS	264
14.5	AUTHOR DETAILS	265

**CAR T-cell Therapy Market Size, Share & Trends by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target Antigen (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), End User & Region - Global Forecast to 2029**

Market Report | 2024-07-22 | 266 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code\*

Country\*

Date

Signature